Lamivudine

"Lamivudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Descriptor ID	D019259
MeSH Number(s)	D03.383.742.680.245.500.950.500 D13.570.230.329.950.500 D13.570.230.500.925.500 D13.570.685.245.500.950.500
Concept/Terms	Lamivudine Lamivudine 3TC 2',3'-Dideoxy-3'-thiacytidine 2',3' Dideoxy 3' thiacytidine Epivir Epivir Lamivudine, (2S-cis)-Isomer Lamivudine, (2S-cis)-Isomer BCH-189 BCH-189 BCH 189 BCH189 GR-109714X GR-109714X GR109714X

Below are MeSH descriptors whose meaning is more general than "Lamivudine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidine Nucleosides [D03.383.742.680]
Cytidine [D03.383.742.680.245]
Deoxycytidine [D03.383.742.680.245.500]
Zalcitabine [D03.383.742.680.245.500.950]
Lamivudine [D03.383.742.680.245.500.950.500]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Deoxyribonucleosides [D13.570.230]
Deoxycytidine [D13.570.230.329]
Zalcitabine [D13.570.230.329.950]
Lamivudine [D13.570.230.329.950.500]
Dideoxynucleosides [D13.570.230.500]
Zalcitabine [D13.570.230.500.925]
Lamivudine [D13.570.230.500.925.500]
Pyrimidine Nucleosides [D13.570.685]
Cytidine [D13.570.685.245]
Deoxycytidine [D13.570.685.245.500]
Zalcitabine [D13.570.685.245.500.950]
Lamivudine [D13.570.685.245.500.950.500]

Below are MeSH descriptors whose meaning is related to "Lamivudine".

Below are MeSH descriptors whose meaning is more specific than "Lamivudine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lamivudine" by people in this website by year, and whether "Lamivudine" was a major or minor topic of these publications.

Bar chart showing 7 publications over 6 distinct years, with a maximum of 2 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1998	0	1	1
1999	0	1	1
2003	0	1	1
2010	1	1	2
2016	0	1	1

Below are the most recent publications written about "Lamivudine" by people in Profiles.

Bolduc P, Roder N, Colgate E, Cheeseman SH. Care of Patients With HIV Infection: Antiretroviral Drug Regimens. FP Essent. 2016 Apr; 443:23-30.

View in: PubMed
Firnhaber C, Azzoni L, Foulkes AS, Gross R, Yin X, Van Amsterdam D, Schulze D, Glencross DK, Stevens W, Hunt G, Morris L, Fox L, Sanne I, Montaner LJ. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.

View in: PubMed
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010 Oct 15; 51(8):963-72.

View in: PubMed
Sophan S, Meng CY, Pean P, Harwell J, Hutton E, Trzmielina S, Somasundaran M, Luzuriaga K, Pugatch D. Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART). Southeast Asian J Trop Med Public Health. 2010 Jan; 41(1):126-37.

View in: PubMed
Ballardin M, Scarpato R, Kotwal GJ, Barale R. In vitro mutagenicity studies of the antiretrovirals AZT, Didanosine, and 3TC and a plant antiviral extract Secomet-V derived from the Trifollium species. Ann N Y Acad Sci. 2005 Nov; 1056:303-10.

View in: PubMed
Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, Kelley M, Bozorgzadeh A. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. Transplant Proc. 2005 Sep; 37(7):3187-9.

View in: PubMed
Alatrakchi N, Koziel MJ. Antiviral T-cell responses and therapy in chronic hepatitis B. J Hepatol. 2003 Oct; 39(4):631-4.

View in: PubMed
Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, Nikodem C, Hall D, Gigliotti M, Robinson P, Boshoff L, Sullivan JL. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003 Mar 01; 187(5):725-35.

View in: PubMed
Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol. 2002 Oct; 68(2):182-7.

View in: PubMed
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999 Dec 16; 341(25):1865-73.

View in: PubMed

People

Explore

Similar Concepts

Top Journals